胸腔镜滑石粉喷洒与经胸管滑石粉浆注入对恶性胸腔积液患者胸膜固定失败率的影响:一项随机临床试验
该开放标签随机临床试验在17家英国医院纳入330例确诊恶性胸腔积液且可接受局部麻醉胸腔镜的患者,随机分为胸腔镜滑石粉喷洒组(166例,中度镇静下喷洒4 g滑石粉)与经胸管滑石粉浆组(164例,局部麻醉下床旁置管后注入4 g无菌滑石粉浆)。主要终点为随机化后90天内胸膜固定失败,喷洒组36/161例(22%)vs 浆液组38/159例(24%),校正OR 0.91(95%CI 0.54-1.55),P=0.74,差值-1.8%(95%CI -10.7%至7.2%)。24项预设次要终点均无统计学显著差异。作者认为研究可能把握度不足以检测小而可能重要的差异。
要点
- 90天胸膜固定失败率:滑石粉喷洒组36/161例(22%)vs 滑石粉浆组38/159例(24%),校正OR 0.91(95%CI 0.54-1.55),P=0.74,无显著差异。
- 24项预设次要终点(含30天和180天失败率、失败时间、住院夜数、胸痛与呼吸困难、生活质量、全因死亡率、胸片不透光百分比)均无统计学显著差异。
- 适用人群为年龄>18岁、确诊恶性胸腔积液且能接受局部麻醉胸腔镜的患者;需诊断性胸腔镜或存在肺不能复张证据者被排除。
- 滑石粉喷洒组在中度镇静下经胸腔镜给4 g滑石粉,滑石粉浆组在局部麻醉下床旁经胸管给4 g无菌滑石粉浆。
- 作者认为该研究可能把握度不足以检测小而可能重要的差异。
适用人群与场景
- 年龄>18岁、确诊恶性胸腔积液且能接受局部麻醉胸腔镜的患者。
- 排除需要诊断性胸腔镜或存在肺不能复张证据的患者。
处置流程与药物剂量
- 滑石粉喷洒组:中度镇静下经胸腔镜给予4 g滑石粉喷洒。
- 滑石粉浆组:局部麻醉下床旁置入胸管后注入4 g无菌滑石粉浆。
研究设计与关键结果
- 开放标签随机临床试验,17家英国医院,2012年8月至2018年4月纳入330例,随访至2018年10月;平均年龄68岁,女性181例(55%);320例(97%)纳入主要终点分析。
- 90天胸膜固定失败率:滑石粉喷洒组36/161例(22%)vs 滑石粉浆组38/159例(24%),校正OR 0.91(95%CI 0.54-1.55),P=0.74,差值-1.8%(95%CI -10.7%至7.2%)。
- 24项预设次要终点均无统计学显著差异,包括30天和180天胸膜固定失败率、胸膜固定失败时间、90天内住院夜数、7/30/90/180天患者报告的胸痛与呼吸困难、30/90/180天健康相关生活质量、全因死亡率、拔管时及30/90/180天胸片不透光百分比。
证据类型、等级与局限
- 证据类型:开放标签随机临床试验。
- 局限:作者指出研究可能把握度不足以检测小而可能重要的差异。
对床旁实践的改变
- 对于确诊恶性胸腔积液且能接受局部麻醉胸腔镜的患者,胸腔镜滑石粉喷洒与经胸管滑石粉浆注入在90天胸膜固定失败率上无显著差异。
- 作者认为该研究可能把握度不足以检测小而可能重要的差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Malignant pleural effusion (MPE) is challenging to manage. Talc pleurodesis is a common and effective treatment. There are no reliable data, however, regarding the optimal method for talc delivery, leading to differences in practice and recommendations.
OBJECTIVE: To test the hypothesis that administration of talc poudrage during thoracoscopy with local anesthesia is more effective than talc slurry delivered via chest tube in successfully inducing pleurodesis.
DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized clinical trial conducted at 17 UK hospitals. A total of 330 participants were enrolled from August 2012 to April 2018 and followed up until October 2018. Patients were eligible if they were older than 18 years, had a confirmed diagnosis of MPE, and could undergo thoracoscopy with local anesthesia. Patients were excluded if they required a thoracoscopy for diagnostic purposes or had evidence of nonexpandable lung.
INTERVENTIONS: Patients randomized to the talc poudrage group (n = 166) received 4 g of talc poudrage during thoracoscopy while under moderate sedation, while patients randomized to the control group (n = 164) underwent bedside chest tube insertion with local anesthesia followed by administration of 4 g of sterile talc slurry.
MAIN OUTCOMES AND MEASURES: The primary outcome was pleurodesis failure up to 90 days after randomization. Secondary outcomes included pleurodesis failure at 30 and 180 days; time to pleurodesis failure; number of nights spent in the hospital over 90 days; patient-reported thoracic pain and dyspnea at 7, 30, 90, and 180 days; health-related quality of life at 30, 90, and 180 days; all-cause mortality; and percentage of opacification on chest radiograph at drain removal and at 30, 90, and 180 days.
RESULTS: Among 330 patients who were randomized (mean age, 68 years; 181 [55%] women), 320 (97%) were included in the primary outcome analysis. At 90 days, the pleurodesis failure rate was 36 of 161 patients (22%) in the talc poudrage group and 38 of 159 (24%) in the talc slurry group (adjusted odds ratio, 0.91 [95% CI, 0.54-1.55]; P = .74; difference, -1.8% [95% CI, -10.7% to 7.2%]). No statistically significant differences were noted in any of the 24 prespecified secondary outcomes.
CONCLUSIONS AND RELEVANCE: Among patients with malignant pleural effusion, thoracoscopic talc poudrage, compared with talc slurry delivered via chest tube, resulted in no significant difference in the rate of pleurodesis failure at 90 days. However, the study may have been underpowered to detect small but potentially important differences.
TRIAL REGISTRATION: ISRCTN Identifier: ISRCTN47845793.
参考来源
- Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M, et al. Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial. JAMA. 2020. PMID: 31804680. doi:10.1001/jama.2019.19997
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。